secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001564590-21-055806
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q3 net loss $21.4M ($0.08/share); revenue falls to $5.5M from $9.4M
-----------------------------------------------------------------------------

- Total revenue $5.5M, down 41% from $9.4M in Q3 2020 due to lower milestone payments and bamlanivimab royalty pause.
- Net loss $21.4M ($0.08 loss per share) vs net loss $2.7M ($0.02 loss) in Q3 2020.
- Cumulative program starts 69, up 35% YoY; partners increased to 35; 5 molecules in the clinic.
- Acquired TetraGenetics to expand capabilities for high-value transmembrane protein targets.
- Post-quarter: Eli Lilly ordered 614K additional doses of bamlanivimab with etesevimab; shipments resumed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021055806/0001564590-21-055806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021055806/abcl-8k_20211109.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-055806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer